Whitehawk Therapeutics (WHWK) Income from Continuing Operations (2010 - 2026)
Whitehawk Therapeutics (WHWK) posted quarterly Income from Continuing Operations of 22194000.0 for Q1 2026, down 130.4% year-over-year from 73016000.0 in Q1 2025, and up 24.26% quarter-over-quarter from 29304000.0 in Q4 2025.
Whitehawk Therapeutics (WHWK) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Income from Continuing Operations for 17 consecutive years, with 22194000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 130.4% year-over-year to 22194000.0; the TTM figure through Mar 2026 stood at 124933000.0 (down 532.98% YoY), while the FY2025 annual figure was 16271000.0, up 74.45% from the prior year.
- Income from Continuing Operations rose to 22194000.0 in Q1 2026 per WHWK's latest filing, from 29304000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 73016000.0 in Q1 2025 and bottomed at 55200000.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 14240941.18 across 5 years, with a median of 16269000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 1089.39% — and 2025, when it soared 471.15%.
- Whitehawk Therapeutics' Income from Continuing Operations stood at 13913000.0 in 2022, then slipped by 16.93% to 16269000.0 in 2023, then climbed by 4.84% to 15482000.0 in 2024, then slumped by 89.28% to 29304000.0 in 2025, then rose by 24.26% to 22194000.0 in 2026.
- Business Quant data shows WHWK's Income from Continuing Operations at 22194000.0 in Q1 2026, 29304000.0 in Q4 2025, and 18235000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - | -16.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.64 Mn |
| Mar 31, 2026 | -22.19 Mn |
| Dec 31, 2025 | -29.30 Mn |
| Sep 30, 2025 | -18.24 Mn |
| Jun 30, 2025 | -55.20 Mn |
| Mar 31, 2025 | 73.02 Mn |
| Dec 31, 2024 | -15.48 Mn |
| Sep 30, 2024 | -12.80 Mn |
| Jun 30, 2024 | -15.88 Mn |
| Mar 31, 2024 | -19.67 Mn |
| Dec 31, 2023 | -16.27 Mn |
| Sep 30, 2023 | -16.30 Mn |
| Jun 30, 2023 | -17.97 Mn |
| Mar 31, 2023 | -15.29 Mn |
| Dec 31, 2022 | -13.91 Mn |
| Sep 30, 2022 | -14.47 Mn |
| Jun 30, 2022 | -18.27 Mn |
| Mar 31, 2022 | -13.86 Mn |
| Dec 31, 2021 | -15.99 Mn |
| Sep 30, 2021 | -87.09 Mn |